Patent ID: 8796250

Claim:
A method for treating a disease or condition in mammal, or a mammalian cell thereof, which is a tumor, chronic myeloid leukemia, inflammation, renal disease, diabetic nephropathy, mesangial proliferative glomerulonephritis, atherosclerosis, restenosis, hypertension-related arterosclerosis, venous bypass graft arterosclerosis, scleroderma, interstitial pulmonary disease, a synovial disorder, arthritis, leukemia or lymphoma mediated by platelet-derived growth factor receptor-beta, where a defect in the receptor itself is involved in “causing” the disease; or functional activity of PDGFR results in the disease symptom and/or phenotype when inappropriately expressed, said method comprising: administering to a subject in need thereof, an effective amount of an aryl urea compound of formula I, a salt form of a compound of Formula I, an isolated or mixed stereoisomer of a compound of Formula I, wherein: A is phenyl, optionally substituted 1, 2 or 3 times by R 3 , wherein each R 3 is independently C 1 -C 5 alkyl, C 1 -C 5 haloalkyl, up to per-haloalkyl, C 1 -C 5 alkoxy, C 1 -C 5 haloalkoxy, up to per-haloalkoxy, halogen, cyano, or nitro; or A is a group of the formula: optionally substituted 1, 2, 3, 4, 5 or 6 times with R 4 wherein each R 4 is independently C 1 -C 5 alkyl or halogen; B is phenylene, optionally substituted 1, 2 or 3 times by R 2 , or naphthylene, optionally substituted optionally substituted 1, 2 or 3 times by R 2 , wherein each R 2 is independently C 1 -C 5 alkyl, C 1 -C 5 haloalkyl, up to per-haloalkyl, C 1 -C 5 alkoxy, C 1 -C 5 haloalkoxy up to per-haloalkoxyl, halogen, cyano or nitro; Q is cyano, —C(O)—R a , or —C(O)—NR b R c , where each R a , R b and R c is independently H or C 1 -C 5 alkyl, L is —O— or —S—, m is an integer 0, 1, 2 or 3, and each R 1 is independently halogen, C 1-5 alkyl, C 1-5 haloalkyl, up to per-haloalkyl, C 1-5 alkoxy, C 1-5 haloalkoxy, up to per-haloalkoxy, N-oxo or N-hydroxy.